Abstract
BackgroundEfficacy and safety of intravenous (IV) tocilizumab (TCZ) were demonstrated in patients (pts) with systemic juvenile idiopathic arthritis (sJIA) in the phase 3 TENDER study1 (WA18221). Study WA28118 (ClinicalTrials.gov, NCT01904292)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have